Literature DB >> 6668546

Pharmacokinetic and pharmacodynamic modelling of trimazosin and its major metabolite.

P A Meredith, A W Kelman, H L Elliott, J L Reid.   

Abstract

The pharmacokinetic and pharmacodynamic profiles of intravenous trimazosin, a postsynaptic alpha 1 antagonist, were analyzed empirically by integrated modelling techniques. The mean terminal elimination half-life for trimazosin was 186 +/- 80 min and the mean elimination half-life of its alkyl hydroxylated metabolite (CP 23445) was 93 +/- 29 min. The placebo-corrected fall in systolic blood pressure after 5 min standing was most appropriately characterized in all subjects by a model that incorporated "effect" compartments for both parent drug and its metabolite.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6668546     DOI： 10.1007/bf01058953

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN： 0090-466X


  10 in total

1.  Statistical estimations in pharmacokinetics.

Authors:  H G Boxenbaum; S Riegelman; R M Elashoff
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

2.  The determination of trimazosin and its metabolite CP23445 in whole blood by high performance liquid chromatography using fluorescence detection.

Authors:  M A Hughes; P A Meredith; H L Elliott
Journal:  J Pharmacol Methods       Date:  1984-08

3.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

4.  Quantitative analysis of the disopyramide concentration-effect relationship.

Authors:  B Whiting; N H Holford; L B Sheiner
Journal:  Br J Clin Pharmacol       Date:  1980-01       Impact factor: 4.335

5.  Modeling of drug response in individual subjects.

Authors:  A W Kelman; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1980-04

6.  The cardiovascular effects of trimazosin.

Authors:  J W Constantine; H J Hess
Journal:  Eur J Pharmacol       Date:  1981-09-11       Impact factor: 4.432

7.  A pharmacodynamic and pharmacokinetic assessment of a new alpha-adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects.

Authors:  H L Elliott; P A Meredith; D J Sumner; K McLean; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

8.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

9.  Modelling theophylline response in individual patients with chronic bronchitis.

Authors:  B Whiting; A W Kelman; J Barclay; G J Addis
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

10.  Effects of tiodazosin, praxosin, trimazosin and phentolamine on blood pressure, heart rate and on pre- and postsynaptic alpha-adrenergic receptors in the rat.

Authors:  J P Buyniski; A W Pircio; J E Schurig; J A Campbell
Journal:  Clin Exp Hypertens       Date:  1980       Impact factor: 1.749
  10 in total
  14 in total

Review 1.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics 1990.

Authors:  G R Matzke; W L St Peter
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

3.  Racial differences in drug responses--a comparative study of trimazosin and alpha 1-adrenoceptor responses in normotensive Caucasians and West Africans.

Authors:  J Vincent; H L Elliott; P A Meredith; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1986-04       Impact factor: 4.335

Review 4.  Pharmacokinetic-pharmacodynamic relationships of alpha-adrenoceptor antagonists.

Authors:  R Donnelly; P A Meredith; H L Elliott
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

5.  Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. III. Peripheral bioavailability and distribution time concepts applied to the evaluation of distribution kinetics.

Authors:  P Veng-Pedersen; W R Gillespie
Journal:  J Pharmacokinet Biopharm       Date:  1987-06

6.  Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol.

Authors:  H L Elliott; P A Meredith; D J Sumner; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1984-05       Impact factor: 4.335

7.  Linear and nonlinear system approaches in pharmacokinetics: how much do they have to offer? II. The response mapping operator (RMO) approach.

Authors:  P Veng-Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1988-10

8.  Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. II. Clearance concepts applied to the evaluation of distribution kinetics.

Authors:  W R Gillespie; P Veng-Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1985-08

9.  Pharmacokinetic-pharmacodynamic model for perindoprilat regional haemodynamic effects in healthy volunteers and in congestive heart failure patients.

Authors:  E Bellissant; J F Giudicelli
Journal:  Br J Clin Pharmacol       Date:  2001-07       Impact factor: 4.335

10.  The effect of cimetidine on the pharmacokinetics, pharmacodynamics and alpha 1-adrenoceptor responsiveness of trimazosin in man.

Authors:  J Vincent; H L Elliott; P A Meredith; D M Hughes; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.